BRPI0416157A - composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase - Google Patents

composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase

Info

Publication number
BRPI0416157A
BRPI0416157A BRPI0416157-2A BRPI0416157A BRPI0416157A BR PI0416157 A BRPI0416157 A BR PI0416157A BR PI0416157 A BRPI0416157 A BR PI0416157A BR PI0416157 A BRPI0416157 A BR PI0416157A
Authority
BR
Brazil
Prior art keywords
alpha
beta
pharmaceutical composition
composition containing
adrenoceptor agonist
Prior art date
Application number
BRPI0416157-2A
Other languages
English (en)
Inventor
Marion Wienrich
Ursula Ebinger
Martin Christian Michel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10352131A external-priority patent/DE10352131A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0416157A publication Critical patent/BRPI0416157A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA CONTENDO UM AGONISTA DE ADRENOCEPTOR BETA-3 E UM ANTAGONISTA ALFA E/OU UM INIBIDOR DE 5-ALFA REDUTASE". A presente invenção refere-se a uma nova combinação para o tratamento de distúrbios da função vesical, abrangendo um antagonista alfa e/ou inibidor de redutase 5-alfa e um agonista de adrenoceptor beta-3.
BRPI0416157-2A 2003-11-03 2004-10-29 composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase BRPI0416157A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10351539 2003-11-03
DE10352131A DE10352131A1 (de) 2003-11-04 2003-11-04 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Antagonisten
PCT/EP2004/012271 WO2005042021A2 (de) 2003-11-03 2004-10-29 Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer

Publications (1)

Publication Number Publication Date
BRPI0416157A true BRPI0416157A (pt) 2007-01-09

Family

ID=34553327

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416157-2A BRPI0416157A (pt) 2003-11-03 2004-10-29 composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase

Country Status (11)

Country Link
US (1) US20050101607A1 (pt)
EP (1) EP1682183A2 (pt)
JP (1) JP2007509896A (pt)
KR (1) KR20060124603A (pt)
AU (1) AU2004285289A1 (pt)
BR (1) BRPI0416157A (pt)
CA (1) CA2544100A1 (pt)
IL (1) IL175292A0 (pt)
MX (1) MXPA06004625A (pt)
RU (1) RU2006119331A (pt)
WO (1) WO2005042021A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092321A1 (ja) 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2009045019A2 (en) * 2007-10-02 2009-04-09 Dong-A Pharm.Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
ES2393525T3 (es) * 2007-11-02 2012-12-26 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de la vejiga hiperactiva
EP2223690A4 (en) * 2007-12-21 2011-02-23 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION USED TO MITIGATE SYMPTOMS OF THE INFINITE URINARY TRACT
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
CN110376295B (zh) * 2019-06-06 2022-03-18 北京华氏康源医药科技有限公司 一种赛洛多辛对映异构体的检测方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828712A1 (en) * 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists
ES2193266T3 (es) * 1995-10-26 2003-11-01 Mitsubishi Pharma Corp Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion.
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6177430B1 (en) * 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
JP2000080032A (ja) * 1998-06-26 2000-03-21 Yamanouchi Pharmaceut Co Ltd 排出障害治療剤
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
JP4132020B2 (ja) * 2001-03-12 2008-08-13 キッセイ薬品工業株式会社 フェノキシ酢酸誘導体の製造中間体およびその使用方法
US7208520B2 (en) * 2001-09-13 2007-04-24 Kissei Pharmaceutical Co., Ltd. Crystals of hydroxynorephedrine derivative
EP1743656A3 (en) * 2002-04-24 2007-03-07 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US7462618B2 (en) * 2003-08-27 2008-12-09 Sun Health Research Institute Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists

Also Published As

Publication number Publication date
CA2544100A1 (en) 2005-05-12
AU2004285289A1 (en) 2005-05-12
IL175292A0 (en) 2006-09-05
WO2005042021A3 (de) 2005-07-21
KR20060124603A (ko) 2006-12-05
US20050101607A1 (en) 2005-05-12
EP1682183A2 (de) 2006-07-26
MXPA06004625A (es) 2006-06-27
JP2007509896A (ja) 2007-04-19
WO2005042021A2 (de) 2005-05-12
RU2006119331A (ru) 2007-12-27

Similar Documents

Publication Publication Date Title
BR0316535A (pt) Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina
BRPI0416157A (pt) composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase
PT1237553E (pt) Combinacao de um inibidor de recaptacao da serotonina e de um antagonista, de um agonista inverso ou de um agonista parcial para o 5-ht2c
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EP2145620A3 (en) Gaboxadol for treating depression and other affective disorders
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BR0315355A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, composição farmacêutica e utilização de um inibidor de re-apreensão de norepinefrina
BR0208813A (pt) Composições contendo imidazotriazinona para a aplicação nasal
BR0300119A (pt) Composição aquosa, e, estrutura compósita
AR047553A1 (es) La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
BRPI0519919A2 (pt) composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BRPI0409690A (pt) associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase
WO2004052858A3 (en) Inhibitors of monoamine uptake
BR0213581A (pt) Uso de um inibidor de recaptação de norepinefrina seletivo
TW200716184A (en) Inhibitor for parakeratosis, pore reducing agent or skin roughening preventing or ameliorating agent and composition for skin care preparation
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.